Pevonedistat plus azacitidine did not meet primary endpoint of EFS
News
BMS opts-in on Evotec’s neurodegenerative medicine
Deal worth $20m plus potential $250m in milestone payments
Moderna submits its COVID-19 vaccine booster to the FDA
Trial showed ‘robust antibody responses’ against Delta variant
GSK’s shingles vaccine Shingrix gains UK license
Jab aimed at adults aged 50 years and older and those at increased risk
IQVIA launches AI-powered medical information contact centre
AI tech designed to improve patient and HCP experience
Heart failure med Jardiance scores MHRA approval
Marketing authorisation covers treatment of heart failure with reduced ejection fraction
JCVI advises booster COVID-19 jab for severely immunosuppressed
Offer is separate to potential booster programme
Early use of Uptravi reduces risk of disease progression in PAH patients
Phase III study finds risk reduced by 52% compared with control group
MHRA nod for AbbVie’s Rinvoq for adults and adolescents with eczema
Large-scale phase III study met all primary and secondary endpoints
NICE, Cochrane to collaborate on delivery of ‘living’ recommendations
Agreement will allow NICE to make ‘efficient and effective’ updates to recommendations in its guideline portfolio
Phase III data for Jardiance shows improvement in HFpEF patients
Data presented at ESC Congress 2021
Roche withdraws US approval for Tecentriq in mTNBC
Metastatic triple-negative breast cancer treatment failed to meet PFS primary endpoint
Dupixent trial meets endpoints for childhood eczema
Sanofi/Regeneron biologic offers alternative to topical steroids
GSK, SK to compare COVID-19 vaccine candidate to AZ’s jab
Phase III trial will use AZ’s COVID-19 vaccine as an active comparator
MHRA authorises UCB’s Bimzelx via post-Brexit licensing pathway
The MHRA decision closely follows a recent positive recommendation from NICE
